media – Page 40 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

After Eli Lilly and Novo Nordisk, who most resembles the “Third Brother of Weight Loss”?

In the global pharmaceutical industry, there is probably no sector like weight loss drug development where only two giants are competing. The number of other players entering the market is not only insufficient to form a complete game, but even a three-way competition is still a future prospect. Eli Lilly and Novo Nordisk control the most powerful brands, the most mature supply systems, and the most complete pace of indication expansion. Eli Lilly’s telposide and Novo Nordisk’s semaglutide are aggressively expanding their market share in the obesity market, which is touted as having a potential of $100 billion. Although competitors are vying for dominance in terms of drug modalities, targets, and mechanisms, products that can truly threaten telposide and semaglutide in the European and American markets remain largely untapped. Many pharmaceutical giants can only lament, “I regret that I don’t have this drug,” when looking at their own pipelines. The ...
- Source: drugdu
- 147
- February 28, 2026
Big news! The first domestic company to pass the evaluation; a blockbuster inhaler with sales exceeding one billion yuan welcomes a game-changer.

Recently, the National Medical Products Administration issued the latest drug approval certificate, and the tiotropium bromide inhalation powder submitted by Shandong Jingwei Pharmaceutical Co., Ltd. was officially approved for marketing. It also passed the consistency evaluation of generic drug quality and efficacy, becoming the first domestic company to pass the evaluation for this product , filling the industry gap of no domestically produced products that have passed the evaluation for more than ten years since the launch of this blockbuster respiratory product. As the world’s first once-daily long-acting anticholinergic drug, tiotropium bromide inhaled powder is a first-line cornerstone treatment for stable chronic obstructive pulmonary disease (COPD), recommended at the highest level by both the global GOLD COPD guidelines and domestic COPD diagnosis and treatment guidelines, indicating a strong clinical need. The original product, Spiriva by Boehringer Ingelheim, entered the Chinese market in 2005 and has long held a leading position ...
- Source: drugdu
- 104
- February 28, 2026
Shanghai Pharmaceuticals’ Rivaroxaban Tablets Receive Singapore Drug Registration Certificate

Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Singapore Food and Drug Administration (HSA), and the drug has been approved for marketing. Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness. In May 2025, Changzhou Pharmaceutical Factory’s rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration, and in October 2025, it obtained a drug registration certificate in Malaysia. The approval of rivaroxaban tablets in three strengths (10mg, 15mg, and 20mg) by the Singapore Food and Drug Administration signifies that the drug is now qualified for sale in Singapore. This will have a positive impact on the company’s expansion ...
- Source: drugdu
- 107
- February 27, 2026
Boehringer Ingelheim’s “Zonartinib” Receives FDA Approval for Treatment-naïve NSCLC

On February 26, the FDA granted zongertinib through a special approval pathway for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) tyrosine kinase domain activating mutations . Zonatitinib, developed by Boehringer Ingelheim, is the world’s first and currently only approved oral HER2 tyrosine kinase inhibitor (TKI). It selectively inhibits HER2 (ERBB2) while avoiding inhibition of wild-type EGFR, thereby minimizing related toxicities. In August 2025, Zonatitinib received approval from both the FDA and the NMPA for the treatment of adult patients with unresectable or metastatic non-squamous NSCLC who have HER2 (ERBB2) tyrosine kinase domain activating mutations and have previously received systemic therapy.With this approval, the target population for zotinib has been further expanded to include individuals who have not received systemic therapy.This approval is based on data from the Phase I Beamion LUNG-1 study. Results showed that the confirmed objective response ...
- Source: drugdu
- 129
- February 27, 2026
Marketing application for recombinant anti-IL-4Rα humanized monoclonal antibody injection accepted

Sansheng Guojian(688336) announced on February 26 that the company recently received an “Acceptance Notice” issued by the National Medical Products Administration, and the new drug application for its independently developed recombinant anti-IL-4Rα humanized monoclonal antibody injection (research code: SSGJ-611) has been accepted. According to the announcement, SSGJ-611 is a monoclonal antibody against IL-4Rα independently developed by the company. It has a novel amino acid sequence and can specifically bind to IL-4Rα, blocking IL-4 and IL-13 signaling, thereby alleviating diseases such as atopic dermatitis. Atopic dermatitis is a chronic, relapsing, inflammatory skin disease. Moderate to severe cases often present with generalized rashes, accompanied by intense itching, dry skin, and crusting. Treatment options are limited, severely impacting quality of life. The global prevalence has gradually increased over the past 30 years, with a prevalence rate of 6.1% among adults in my country. The announcement stated that the Phase III clinical trial conducted ...
- Source: drugdu
- 131
- February 27, 2026
Genrix Bio’s marketing application for talicibazine injection for the treatment of adult seasonal allergic rhinitis has been accepted.

Genrix Bio announced on the evening of February 26 that its Phase III clinical trial of “Telicibaimab Injection (GR1802 Injection)” for the indication of adult seasonal allergic rhinitis has met the primary endpoint. The company has submitted a new drug application for this indication to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and it has been accepted (acceptance number: CXSS2600031). According to available information, telithiasismab injection is a recombinant fully human anti-IL-4Rα monoclonal antibody independently developed by the company, targeting IL-4Rα. This drug specifically binds to human IL-4Rα on the cell surface, blocking the binding of IL-4 and IL-13 to IL-4Rα, inhibiting downstream STAT6 phosphorylation, and suppressing CD23 upregulation, thereby inhibiting Th2-type inflammatory responses mediated by IL-4 or IL-13. According to reports, the new drug application for telixirizabab injection for the treatment of moderate to severe atopic dermatitis in adults was accepted in September ...
- Source: drugdu
- 128
- February 27, 2026
13.8 billion! Leading domestic imaging equipment manufacturer sees significant revenue growth.

Today, United Imaging Healthcare released its preliminary financial results for 2025. The core indicators in the 2025 financial report are all positive, with revenue, net profit and other key indicators increasing by more than 30% . 01 Core Driver Significant performance growth Specifically, in 2025, United Imaging Healthcare’s total revenue reached RMB 13.821 billion, a year-on-year increase of 34.18%, and its net profit attributable to the parent company was RMB 1.888 billion, a year-on-year increase of 49.60%. In addition, many indicators showed significant growth, among which the net profit excluding non-recurring items was RMB 1.788 billion, a substantial year-on-year increase of 77.01%. Based on its outstanding performance in 2025, United Imaging Healthcare’s stock price soared today, with trading volume and turnover skyrocketing. As of 9:40 a.m. today, the highest stock price reached 133.53 yuan, with a single-day increase of up to 5.64%, and a total market value of 108.5 billion ...
- Source: drugdu
- 176
- February 27, 2026
IL-4R antibody submitted for market approval

On February 25, the marketing application of Akeso Biopharma’s IL-4R antibody mandocimab injection was accepted by the NMPA. In August 2025, Akeso announced that its IL-4R antibody, mandocizumab, had achieved all efficacy endpoints in a Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and planned to apply for market approval. Based on inter-study comparisons (non-head-to-head), the efficacy data of mandocizumab is superior to that of the marketed product Dupixent, and it is being further expanded to adolescents. Sanofi’s IL-4R antibody, Dupixent, is the world’s best-selling autoimmune drug, with sales of $18.5 billion in 2025. Image source: Medical Notes Conclusion In the field of autoimmune diseases, Akeso Biopharma will focus on developing dual-target iterative products. The IL-4R/ST2 bispecific antibody AK139 is actively advancing its clinical development and has now reached the Phase II clinical trial stage. https://news.yaozh.com/archive/47273.html
- Source: drugdu
- 105
- February 27, 2026
The Next Blockbuster Drug

Drugs for IgA nephropathy are on the eve of explosive growth. 01 The Next Blockbuster Drug The scarcity of marketed drugs and vast market space once made IgA nephropathy a highly contested battleground for innovative pharmaceutical companies. As the world’s first approved etiological treatment for IgA nephropathy, budesonide enteric coated capsules (brand name: Nefecon / Tarpeyo / 耐赋康) is regarded as the next blockbuster drug. Southwest Securities predicts that sales of budesonide enteric coated capsules could reach 5 billion yuan by 2030. Budesonide enteric coated capsules have already begun to show clear market leadership potential. In 2024, before being covered by medical insurance, the product achieved sales of 353 million yuan in seven months. With volume growth driven by insurance coverage and expanded indications in 2025, sales of budesonide enteric coated capsules surged to over 500 million yuan in Q1–Q3 2025, representing a year-on-year increase of 3,699.89%. At this rate, ...
- Source: drugdu
- 168
- February 27, 2026
【EXPERT Q&A】How can the compliance assessment of in vitro diagnostics (IVDR) in the European Union be carried out in a standardized and efficient manner?

Drugdu.com expert’s response: I. Preliminary Preparation: Clarify Classification and Regulatory Foundations 1. Product Classification According to Annex VIII of the IVDR Regulation (EU 2017/746), in vitro diagnostic devices are categorized into four risk classes: A, B, C, and D: Class A: Low risk (e.g., general laboratory reagents). Non-sterile Class A devices can be self-declared, while sterile Class A devices require notified body involvement. Class B: Medium-low risk (e.g., pregnancy test kits). Requires notified body review of technical documentation and quality management system (QMS). Class C: Medium-high risk (e.g., tumor marker tests). Requires comprehensive notified body review. Class D: High risk (e.g., HIV or HCV tests). Subject to the strictest review, including performance evaluation and clinical data. 2. Regulations and Standards Core Regulation: IVDR (EU 2017/746) and its accompanying guidelines. Harmonized Standards: ISO 13485 (QMS), ISO 14971 (risk management). Unique Device Identification (UDI): Must be registered in the EUDAMED database and ...
- Source: drugdu
- 141
- February 27, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.